Free Trial

Protalix BioTherapeutics Q4 2023 Earnings Report

Protalix BioTherapeutics logo
$1.64 -0.03 (-1.80%)
(As of 12/3/2024 ET)

Protalix BioTherapeutics EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.03
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Protalix BioTherapeutics Revenue Results

Actual Revenue
$10.49 million
Expected Revenue
$8.15 million
Beat/Miss
Beat by +$2.34 million
YoY Revenue Growth
N/A

Protalix BioTherapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)

WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…

Click here to see a unique election-year trade

Protalix BioTherapeutics Earnings Headlines

PLX: Self-Sustaining Rise to Lead in Renal Rare Disease
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
See More Protalix BioTherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Protalix BioTherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protalix BioTherapeutics and other key companies, straight to your email.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

View Protalix BioTherapeutics Profile

More Earnings Resources from MarketBeat